Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Fulcrum Therapeutics (Nasdaq: FULC) announced inducement equity grants for new hires under its 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The company granted an aggregate of 270,000 non-statutory stock options to two employees and a 50,000 performance-based option to a third employee, each with an exercise price of $9.02 per share (closing price on the grant effective date, Nov 3, 2025).

The 270,000 options carry a 10-year term and vest over four years (25% after one year, then 6.25% quarterly over 12 quarters). The 50,000 performance option vests after 12 months subject to continued eligibility and achievement of predefined performance objectives, and will be forfeited if objectives are not met within six months of the grant date.

CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).

Fulcrum granted two of the new employees an aggregate of 270,000 options to purchase shares of the company’s common stock and one employee a 50,000 performance-based option to purchase shares of the company’s common stock, each at an exercise price of $9.02 per share, the closing price per share of Fulcrum’s common stock as reported on the grant effective date, November 3, 2025. The aggregate 270,000 options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and an additional 6.25% of the shares vesting in equal quarterly installments over the twelve successive quarters following the first anniversary, subject to the applicable employee’s continued service with the company through the applicable vesting dates. The performance-based stock option will fully vest twelve months from the applicable employee’s start date, subject to the employee continuing to be an “eligible participant” (as defined in such plan) through the vesting date and achievement of certain pre-defined performance objectives. If the employee fails to achieve all performance objectives within six months of the grant date, the performance-based stock option will be forfeited in its entirety.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit http://www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.

Contact:

Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856

FAQ

What inducement grants did Fulcrum Therapeutics (FULC) announce on November 7, 2025?

Fulcrum announced grants totaling 320,000 options (270,000 service-based and 50,000 performance-based) at an exercise price of $9.02 per share, effective Nov 3, 2025.

How do the 270,000 options granted by FULC vest and expire?

The 270,000 options have a 10-year term and vest over 4 years: 25% after one year, then 6.25% each quarter for the next 12 quarters.

What are the vesting conditions for the 50,000 performance-based option granted by FULC?

The 50,000 performance option fully vests after 12 months subject to continued eligibility and achievement of specified performance objectives; it is forfeited if objectives are not met within six months of the grant date.

At what price were Fulcrum's inducement options granted (FULC)?

Each option was granted with an exercise price of $9.02 per share, equal to the closing price on the grant effective date, Nov 3, 2025.

Why did Fulcrum grant inducement options under Nasdaq Listing Rule 5635(c)(4)?

The grants were made as inducements material to new employees entering employment, consistent with Nasdaq Listing Rule 5635(c)(4).

Will Fulcrum's inducement grants immediately dilute existing shareholders (FULC)?

The announcement discloses the number of options granted and terms but does not quantify immediate dilution or outstanding share count; investors should review the company's equity disclosure for dilution impact.